PharmaPoint:偏頭痛 - EU5個國家的醫藥品的預測與市場分析
PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 149 Pages
|PharmaPoint:偏頭痛 - EU5個國家的醫藥品的預測與市場分析 PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 149 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Each of the countries included in this report provide guidelines for the treatment of migraine. According to GlobalData's high-prescriber survey, the US, UK and Japan strongly adhere to their own national guidelines; however, the majority of the physicians from other EU countries (France, Germany, Italy and Spain) follow European guidelines such as the European Headache Federation (EHF) and European Federation of Neurological Societies (EFNS) guidelines.